Levilimab is an anti-IL-6 monoclonal antibody initially developed to treat rheumatoid arthritis. In 2020, it was approved as a treatment for COVID-19 in Russia.[1][2][3]
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 52.14.184.10